Sign up to save your podcasts
Or
Share 🧬 The Double-Edged Blade of Antithrombotic Therapy in LVADs
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
🧬 The Double-Edged Blade of Antithrombotic Therapy in LVADs
🫀 New insights from EUROMACS registry!
The latest JACC study explores the delicate ⚖️ trade-off between bleeding 🩸 and ischemic 🧠 events in LVAD patients. While HM3 reduces thrombotic risks, bleeding remains the dominant threat. Time to rethink the "one-size-fits-all" anticoagulation 🧪. Personalized strategies like LD-DOACs & lower INR targets may be the next frontier 🚀. Editorial call to action included!
📘 #Cardiology #LVAD #PrecisionMedicine #JACC #HM3 #BleedingRisk #Anticoagulation
👉 Read more & let's discuss.
View all episodes
By Dr RR Baliga, MD, MBA
5
66 ratings
🫀 New insights from EUROMACS registry!
The latest JACC study explores the delicate ⚖️ trade-off between bleeding 🩸 and ischemic 🧠 events in LVAD patients. While HM3 reduces thrombotic risks, bleeding remains the dominant threat. Time to rethink the "one-size-fits-all" anticoagulation 🧪. Personalized strategies like LD-DOACs & lower INR targets may be the next frontier 🚀. Editorial call to action included!
📘 #Cardiology #LVAD #PrecisionMedicine #JACC #HM3 #BleedingRisk #Anticoagulation
👉 Read more & let's discuss.
More shows like Dr RR Baliga's "Got Knowledge Doc" Podkast
View all
This Week in Cardiology
901 Listeners
The Curbsiders Internal Medicine Podcast
3,379 Listeners
The Mel Robbins Podcast
20,443 Listeners